Advertisement
Results of the study showed that Grade II and III lysis was achieved in93% of patients treated with the Trellis catheter and 79% of patients treatedwith CDT even though thrombolytic doses and infusion durations were less withthe Trellis catheter than with conventional CDT. Major hemorrhage wasreported in none of the Trellis catheter patients and in 8.5% of patientstreated with CDT. The per-patient cost of therapy was $3,697 for the Trelliscatheter and $5,473 for CDT. This cost reduction is due to approximately 80%of the Trellis catheter patients being treated in the single-setting of theinterventional suite with less time required for follow-up monitoring in acostly critical care unit compared with CDT patients.
Advertisement
The study, which was authored by Daniel E. Hilleman, PharmD (Department ofPharmacy Practice, Creighton University School of Pharmacy, Omaha, NE) andMahmood K. Razavi, MD (Department of Vascular and Interventional Radiology,Stanford University Hospital, Stanford, CA), compared retrospectivelycollected data from 147 patients treated for DVT with the Trellis-8 infusioncatheter at 45 hospitals in the U.S. and three hospitals outside the U.S. witha meta-analysis of 14 published studies in the medical literature in which CDTwas performed on a minimum of 15 patients with DVT.
"We are gratified to see this rigorously-analyzed comparative datapublished in a major medical journal," stated Scott Cramer, President and CEOof Bacchus Vascular. "We continue to believe in both the strong clinical andeconomic utility of the Trellis infusion catheter as recognition increases inthe medical community of the benefit of early DVT intervention in combatingpost-thrombotic syndrome and potential future DVT events."
About Bacchus Vascular
Bacchus Vascular, Inc. is a privately held medical device companydedicated to the treatment of peripheral vascular disease. Dr. ThomasFogarty, a noted inventor and cardiovascular surgeon, founded the company withthe vision of transforming blood clot removal from peripheral blood vesselsinto a fast, simple, minimally-invasive catheter-based procedure. Thousandsof patients suffering from DVT and other occlusive vascular diseases have beentreated worldwide to date using the company's Trellis(R) Peripheral InfusionSystem and other products.
For more information, visit http://www.bacchusvascular.com.
SOURCE Bacchus Vascular Inc.
